Difference between revisions of "Template:Ionotropic glutamate receptor modulators"
Jump to navigation
Jump to search
imported>Medgirl131 |
imported>Medgirl131 |
||
| (20 intermediate revisions by 7 users not shown) | |||
| Line 3: | Line 3: | ||
| title = [[Ionotropic glutamate receptor]] [[receptor modulator|modulator]]s | | title = [[Ionotropic glutamate receptor]] [[receptor modulator|modulator]]s | ||
| state = {{{state<includeonly>|collapsed</includeonly>}}} | | state = {{{state<includeonly>|collapsed</includeonly>}}} | ||
| − | | | + | | bodyclass = hlist |
| groupstyle = text-align:center; | | groupstyle = text-align:center; | ||
| Line 18: | Line 18: | ||
* [[Quisqualic acid]] | * [[Quisqualic acid]] | ||
* [[Willardiine]]; ''Positive allosteric modulators:'' [[Aniracetam]] | * [[Willardiine]]; ''Positive allosteric modulators:'' [[Aniracetam]] | ||
| + | * [[BIIB-104|BIIB-104 (PF-04958242)]] | ||
* [[Cyclothiazide]] | * [[Cyclothiazide]] | ||
* [[CX-516]] | * [[CX-516]] | ||
| Line 39: | Line 40: | ||
* [[Oxiracetam]] | * [[Oxiracetam]] | ||
* [[PEPA (drug)|PEPA]] | * [[PEPA (drug)|PEPA]] | ||
| − | |||
* [[Piracetam]] | * [[Piracetam]] | ||
* [[Pramiracetam]] | * [[Pramiracetam]] | ||
| Line 68: | Line 68: | ||
* [[Cyclopropane]] | * [[Cyclopropane]] | ||
* [[Enflurane]] | * [[Enflurane]] | ||
| − | * [[Ethanol]] | + | * [[Alcohol (drug)|Ethanol (alcohol)]] |
* [[Evans blue]] | * [[Evans blue]] | ||
* [[GYKI-52466]] | * [[GYKI-52466]] | ||
| Line 78: | Line 78: | ||
* [[Pregnenolone sulfate]] | * [[Pregnenolone sulfate]] | ||
* [[Sevoflurane]] | * [[Sevoflurane]] | ||
| − | * [[Talampanel]] | + | * [[Talampanel]]; ''Unknown/unsorted antagonists:'' [[Minocycline]] |
| group2 = {{abbrlink|KAR|Kainate receptor}} | | group2 = {{abbrlink|KAR|Kainate receptor}} | ||
| Line 117: | Line 117: | ||
* [[UBP-302]]; ''Negative allosteric modulators:'' [[Barbiturates]] (e.g., [[pentobarbital]], [[sodium thiopental]]) | * [[UBP-302]]; ''Negative allosteric modulators:'' [[Barbiturates]] (e.g., [[pentobarbital]], [[sodium thiopental]]) | ||
* [[Enflurane]] | * [[Enflurane]] | ||
| − | * [[Ethanol]] | + | * [[Alcohol (drug)|Ethanol (alcohol)]] |
* [[Evans blue]] | * [[Evans blue]] | ||
* [[NS-3763]] | * [[NS-3763]] | ||
| Line 155: | Line 155: | ||
* [[Neboglamine|Neboglamine (nebostinel)]] | * [[Neboglamine|Neboglamine (nebostinel)]] | ||
* [[Rapastinel|Rapastinel (GLYX-13)]] | * [[Rapastinel|Rapastinel (GLYX-13)]] | ||
| − | * [[Sarcosine]]; ''Polyamine site agonists:'' [[Spermidine]] | + | * [[Sarcosine]]; ''Polyamine site agonists:'' [[Neomycin]] |
| + | * [[Spermidine]] | ||
* [[Spermine]]; ''Other positive allosteric modulators:'' [[24S-Hydroxycholesterol|24''S''-Hydroxycholesterol]] | * [[Spermine]]; ''Other positive allosteric modulators:'' [[24S-Hydroxycholesterol|24''S''-Hydroxycholesterol]] | ||
* {{abbrlink|DHEA|Dehydroepiandrosterone}} ([[prasterone]]) | * {{abbrlink|DHEA|Dehydroepiandrosterone}} ([[prasterone]]) | ||
| Line 161: | Line 162: | ||
* [[Epipregnanolone sulfate]] | * [[Epipregnanolone sulfate]] | ||
* [[Pregnenolone sulfate]] | * [[Pregnenolone sulfate]] | ||
| + | * [[SAGE-201]] | ||
| + | * [[SAGE-301]] | ||
* [[SAGE-718]] | * [[SAGE-718]] | ||
| Line 184: | Line 187: | ||
* [[cis-1-(phenanthrene-2-carbonyl)piperazine-2,3-dicarboxylic acid|PPDA]] | * [[cis-1-(phenanthrene-2-carbonyl)piperazine-2,3-dicarboxylic acid|PPDA]] | ||
* [[SDZ-220581]] | * [[SDZ-220581]] | ||
| − | * [[Selfotel]]; '' | + | * [[Selfotel]]; ''Glycine site antagonists:'' [[4-Chlorokynurenine|4-Cl-KYN (AV-101)]] |
| − | * [[ | + | * [[5,7-Dichlorokynurenic acid|5,7-DCKA]] |
| − | * [[ | + | * [[7-Chlorokynurenate|7-CKA]] |
| − | * [[ | + | * [[1-Aminocyclopropane-1-carboxylic acid|ACC]] |
| − | * [[ | + | * [[ACEA-1011]] |
| − | * [[ | + | * [[ACEA-1328]] |
| − | * [[ | + | * [[Apimostinel|Apimostinel (NRX-1074)]] |
| − | * [[MDL- | + | * [[AV-101]] |
| − | * [[ | + | * [[Carisoprodol]] |
| − | * [[ | + | * [[CGP-39653]] |
| + | * [[CNQX]] | ||
| + | * [[Cycloserine|<small>D</small>-Cycloserine]] | ||
| + | * [[DNQX]] | ||
| + | * [[Felbamate]] | ||
| + | * [[Gavestinel]] | ||
| + | * [[GV-196771]] | ||
| + | * [[Harkoseride]] | ||
| + | * [[Kynurenic acid]] | ||
| + | * [[Kynurenine]]<!--As a prodrug of kynurenic acid--> | ||
| + | * [[L-689560]] | ||
| + | * [[L-701324]] | ||
| + | * [[Licostinel|Licostinel (ACEA-1021)]] | ||
| + | * [[LU-73068]] | ||
| + | * [[MDL-105519]] | ||
| + | * [[Meprobamate]] | ||
| + | * [[MRZ 2/576]] | ||
| + | * [[PNQX]] | ||
| + | * [[Rapastinel|Rapastinel (GLYX-13)]] | ||
| + | * [[ZD-9379]]; ''Polyamine site antagonists:'' [[Arcaine]] | ||
| + | * [[Co 101676]] | ||
| + | * [[1,3-Diaminopropane|Diaminopropane]] | ||
| + | * [[Diethylenetriamine]] | ||
| + | * [[Huperzine A]] | ||
| + | * [[Putrescine]]; ''Uncompetitive pore blockers (mostly dizocilpine site):'' [[2-MDP]] | ||
* [[3-HO-PCP]] | * [[3-HO-PCP]] | ||
* [[3-MeO-PCE]] | * [[3-MeO-PCE]] | ||
| Line 203: | Line 230: | ||
* [[Alpha-Endopsychosin|α-Endopsychosin]] | * [[Alpha-Endopsychosin|α-Endopsychosin]] | ||
* [[Alaproclate]] | * [[Alaproclate]] | ||
| + | * [[Alazocine|Alazocine (SKF-10047)]] | ||
* [[Amantadine]] | * [[Amantadine]] | ||
* [[Aptiganel]] | * [[Aptiganel]] | ||
| Line 215: | Line 243: | ||
* [[Dexoxadrol]] | * [[Dexoxadrol]] | ||
* [[Dextrallorphan]] | * [[Dextrallorphan]] | ||
| + | * [[Dextromethadone]] | ||
| + | * [[Dextromethorphan]] | ||
| + | * [[Dextrorphan]] | ||
* [[Dieticyclidine]] | * [[Dieticyclidine]] | ||
* [[Diphenidine]] | * [[Diphenidine]] | ||
| Line 230: | Line 261: | ||
* [[Ketobemidone]] | * [[Ketobemidone]] | ||
* [[Lanicemine]] | * [[Lanicemine]] | ||
| + | * [[Levomethadone]] | ||
| + | * [[Levomethorphan]] | ||
| + | * [[Levomilnacipran]] | ||
| + | * [[Levorphanol]] | ||
* [[Loperamide]] | * [[Loperamide]] | ||
* [[Memantine]] | * [[Memantine]] | ||
| − | * [[Methadone]] | + | * [[Methadone]] |
| − | * [[Methorphan]] | + | * [[Methorphan]] |
| − | |||
* [[Methoxetamine]] | * [[Methoxetamine]] | ||
* [[Methoxphenidine]] | * [[Methoxphenidine]] | ||
* [[Milnacipran]] | * [[Milnacipran]] | ||
| − | * [[Morphanol]] | + | * [[Morphanol]] |
| − | |||
* [[NEFA (drug)|NEFA]] | * [[NEFA (drug)|NEFA]] | ||
| − | |||
* [[Neramexane]] | * [[Neramexane]] | ||
* [[Nitromemantine]] | * [[Nitromemantine]] | ||
| − | |||
* [[Noribogaine]] | * [[Noribogaine]] | ||
* [[Norketamine]] | * [[Norketamine]] | ||
| Line 262: | Line 293: | ||
* [[Tenocyclidine]] | * [[Tenocyclidine]] | ||
* [[Tiletamine]] | * [[Tiletamine]] | ||
| − | * [[Tramadol | + | * [[Tramadol]]; ''Ifenprodil (NR2B) site antagonists:'' |
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
* [[Besonprodil]] | * [[Besonprodil]] | ||
| − | * [[ | + | * [[Buphenine|Buphenine (nylidrin)]] |
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
* [[CO-101244|CO-101244 (PD-174494)]] | * [[CO-101244|CO-101244 (PD-174494)]] | ||
* [[Eliprodil]] | * [[Eliprodil]] | ||
* [[Haloperidol]] | * [[Haloperidol]] | ||
| − | |||
* [[Isoxsuprine]] | * [[Isoxsuprine]] | ||
| − | * [[ | + | * [[Radiprodil|Radiprodil (RGH-896)]] |
* [[Rislenemdaz|Rislenemdaz (CERC-301, MK-0657)]] | * [[Rislenemdaz|Rislenemdaz (CERC-301, MK-0657)]] | ||
| − | * [[ | + | * [[Ro 8-4304]] |
| − | * [[ | + | * [[Ro 25-6981]] |
| − | * [[Traxoprodil]]; '' | + | * [[Safaprodil]] |
| − | * [[ | + | * [[Traxoprodil|Traxoprodil (CP-101606)]]; ''NR2A-selective antagonists:'' [[MPX-004]] |
| − | * [[ | + | * [[MPX-007]] |
| − | * [[ | + | * [[TCN-201]] |
| − | + | * [[TCN-213]]; ''Cations:'' [[Hydrogen]] | |
| − | * [[ | + | * [[Magnesium]] |
| − | * [[ | + | * [[Zinc]]; ''Alcohols/volatile anesthetics/related:'' [[Benzene]] |
| + | * [[Butane]] | ||
* [[Chloroform]] | * [[Chloroform]] | ||
* [[Cyclopropane]] | * [[Cyclopropane]] | ||
| − | * [[ | + | * [[Desflurane]] |
* [[Diethyl ether]] | * [[Diethyl ether]] | ||
* [[Enflurane]] | * [[Enflurane]] | ||
| − | * [[Ethanol]] | + | * [[Alcohol (drug)|Ethanol (alcohol)]] |
| + | * [[Halothane]] | ||
| + | * [[Hexanol]] | ||
| + | * [[Isoflurane]] | ||
| + | * [[Methoxyflurane]] | ||
| + | * [[Nitrous oxide]] | ||
| + | * [[Octanol]] | ||
| + | * [[Sevoflurane]] | ||
| + | * [[Toluene]] | ||
| + | * [[1,1,1-Trichloroethane|Trichloroethane]] | ||
| + | * [[2,2,2-Trichloroethanol|Trichloroethanol]] | ||
| + | * [[Trichloroethylene]] | ||
| + | * [[Ethyl carbamate|Urethane]] | ||
| + | * [[Xenon]] | ||
| + | * [[Xylene]]; ''Unknown/unsorted antagonists:'' [[ARR-15896]] | ||
| + | * [[Bumetanide]] | ||
| + | * [[Caroverine]] | ||
| + | * [[Conantokin]] | ||
| + | * [[D-α-Aminoadipate|<small>D</small>-αAA]] | ||
| + | * [[Dexanabinol]] | ||
* [[Flufenamic acid]] | * [[Flufenamic acid]] | ||
* [[Flupirtine]] | * [[Flupirtine]] | ||
| + | * [[FPL-12495]] | ||
| + | * [[FR-115427]] | ||
* [[Furosemide]] | * [[Furosemide]] | ||
| − | * [[ | + | * [[Hodgkinsine]] |
* [[Ipenoxazone|Ipenoxazone (MLV-6976)]] | * [[Ipenoxazone|Ipenoxazone (MLV-6976)]] | ||
| − | * [[ | + | * [[MDL-27266]] |
* [[Metaphit]]<!--Irreversible--> | * [[Metaphit]]<!--Irreversible--> | ||
| − | * [[ | + | * [[Minocycline]] |
| + | * [[2-Methyl-6-(phenylethynyl)pyridine|MPEP]] | ||
* [[Niflumic acid]] | * [[Niflumic acid]] | ||
| + | * [[Pentamidine]] | ||
* [[Pentamidine isethionate]] | * [[Pentamidine isethionate]] | ||
* [[Piretanide]] | * [[Piretanide]] | ||
| − | * [[ | + | * [[Psychotridine]] |
* [[Transcrocetin]] ([[saffron]]) | * [[Transcrocetin]] ([[saffron]]) | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | + | * '''Unsorted:''' ''Allosteric modulators:'' [[AGN-241751]] | |
| − | }}<noinclude> | + | |below = |
| − | {{ | + | * '''''See also:''' [[Template:Receptor modulators|Receptor/signaling modulators]]'' |
| + | * ''[[Template:Metabotropic glutamate receptor modulators|Metabotropic glutamate receptor modulators]]'' | ||
| + | * ''[[Template:Glutamate metabolism and transport modulators|Glutamate metabolism/transport modulators]]'' | ||
| + | }} | ||
| + | <noinclude> | ||
| + | {{Collapsible option}} | ||
[[Category:Drug templates by receptor, channel, or pump]] | [[Category:Drug templates by receptor, channel, or pump]] | ||
</noinclude> | </noinclude> | ||
Latest revision as of 17:35, 1 August 2018
Initial visibility: currently defaults to autocollapse
To set this template's initial visibility, the |state= parameter may be used:
|state=collapsed:{{Ionotropic glutamate receptor modulators|state=collapsed}}to show the template collapsed, i.e., hidden apart from its title bar|state=expanded:{{Ionotropic glutamate receptor modulators|state=expanded}}to show the template expanded, i.e., fully visible|state=autocollapse:{{Ionotropic glutamate receptor modulators|state=autocollapse}}
If the |state= parameter in the template on this page is not set, the template's initial visibility is taken from the |default= parameter in the Collapsible option template. For the template on this page, that currently evaluates to autocollapse.